Antibody Subclass and Glycosylation Shift Following Effective TB Treatment
With an estimated 25% of the global population infected with Mycobacterium tuberculosis (Mtb), tuberculosis (TB) remains a leading cause of death by infectious diseases. Humoral immunity following TB treatment is largely uncharacterized, and antibody profiling could provide insights into disease res...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.679973/full |
| _version_ | 1818439278606155776 |
|---|---|
| author | Patricia S. Grace Patricia S. Grace Sepideh Dolatshahi Lenette L. Lu Adam Cain Fabrizio Palmieri Linda Petrone Sarah M. Fortune Tom H. M. Ottenhoff Douglas A. Lauffenburger Delia Goletti Simone A. Joosten Galit Alter |
| author_facet | Patricia S. Grace Patricia S. Grace Sepideh Dolatshahi Lenette L. Lu Adam Cain Fabrizio Palmieri Linda Petrone Sarah M. Fortune Tom H. M. Ottenhoff Douglas A. Lauffenburger Delia Goletti Simone A. Joosten Galit Alter |
| author_sort | Patricia S. Grace |
| collection | DOAJ |
| description | With an estimated 25% of the global population infected with Mycobacterium tuberculosis (Mtb), tuberculosis (TB) remains a leading cause of death by infectious diseases. Humoral immunity following TB treatment is largely uncharacterized, and antibody profiling could provide insights into disease resolution. Here we focused on the distinctive TB-specific serum antibody features in active TB disease (ATB) and compared them with latent TB infection (LTBI) or treated ATB (txATB). As expected, di-galactosylated glycan structures (lacking sialic acid) found on IgG-Fc differentiated LTBI from ATB, but also discriminated txATB from ATB. Moreover, TB-specific IgG4 emerged as a novel antibody feature that correlated with active disease, elevated in ATB, but significantly diminished after therapy. These findings highlight 2 novel TB-specific antibody changes that track with the resolution of TB and may provide key insights to guide TB therapy. |
| first_indexed | 2024-12-14T17:53:55Z |
| format | Article |
| id | doaj.art-fa7779f79cd742d18b14d6b5209ea8be |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-14T17:53:55Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-fa7779f79cd742d18b14d6b5209ea8be2022-12-21T22:52:35ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-07-011210.3389/fimmu.2021.679973679973Antibody Subclass and Glycosylation Shift Following Effective TB TreatmentPatricia S. Grace0Patricia S. Grace1Sepideh Dolatshahi2Lenette L. Lu3Adam Cain4Fabrizio Palmieri5Linda Petrone6Sarah M. Fortune7Tom H. M. Ottenhoff8Douglas A. Lauffenburger9Delia Goletti10Simone A. Joosten11Galit Alter12Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United StatesDepartment of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA, United StatesDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, United StatesDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United StatesRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United StatesClinical Department, National Institute for Infectious Diseases (INMI), IRCCS L. Spallanzani, Rome, ItalyDepartment of Epidemiology and Preclinical Research, National Institute for Infectious Diseases IRCCS (INMI) L. Spallanzani, Rome, ItalyDepartment of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA, United StatesDepartment of Infectious Disease, Leiden University Medical Center, Leiden, NetherlandsDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United StatesDepartment of Epidemiology and Preclinical Research, National Institute for Infectious Diseases IRCCS (INMI) L. Spallanzani, Rome, ItalyDepartment of Infectious Disease, Leiden University Medical Center, Leiden, NetherlandsRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United StatesWith an estimated 25% of the global population infected with Mycobacterium tuberculosis (Mtb), tuberculosis (TB) remains a leading cause of death by infectious diseases. Humoral immunity following TB treatment is largely uncharacterized, and antibody profiling could provide insights into disease resolution. Here we focused on the distinctive TB-specific serum antibody features in active TB disease (ATB) and compared them with latent TB infection (LTBI) or treated ATB (txATB). As expected, di-galactosylated glycan structures (lacking sialic acid) found on IgG-Fc differentiated LTBI from ATB, but also discriminated txATB from ATB. Moreover, TB-specific IgG4 emerged as a novel antibody feature that correlated with active disease, elevated in ATB, but significantly diminished after therapy. These findings highlight 2 novel TB-specific antibody changes that track with the resolution of TB and may provide key insights to guide TB therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2021.679973/fullantibodiestuberculosisIgG4Fc-glycosylationTB therapy |
| spellingShingle | Patricia S. Grace Patricia S. Grace Sepideh Dolatshahi Lenette L. Lu Adam Cain Fabrizio Palmieri Linda Petrone Sarah M. Fortune Tom H. M. Ottenhoff Douglas A. Lauffenburger Delia Goletti Simone A. Joosten Galit Alter Antibody Subclass and Glycosylation Shift Following Effective TB Treatment Frontiers in Immunology antibodies tuberculosis IgG4 Fc-glycosylation TB therapy |
| title | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_full | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_fullStr | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_full_unstemmed | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_short | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_sort | antibody subclass and glycosylation shift following effective tb treatment |
| topic | antibodies tuberculosis IgG4 Fc-glycosylation TB therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.679973/full |
| work_keys_str_mv | AT patriciasgrace antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT patriciasgrace antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT sepidehdolatshahi antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT lenettellu antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT adamcain antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT fabriziopalmieri antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT lindapetrone antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT sarahmfortune antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT tomhmottenhoff antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT douglasalauffenburger antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT deliagoletti antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT simoneajoosten antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT galitalter antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment |